{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:12:57Z","timestamp":1789513977791,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T00:00:00Z","timestamp":1474243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/onc.2016.309","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T10:10:03Z","timestamp":1474279803000},"page":"1417-1429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Non-canonical NF\u03baB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NF\u03baB pathway"],"prefix":"10.1038","volume":"36","author":[{"given":"P","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Vijayaragavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Banoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,19]]},"reference":[{"key":"BFonc2016309_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K . Medical progress multiple myeloma. N Engl J Med 2011; 364: 1046\u20131060.","journal-title":"N Engl J Med"},{"key":"BFonc2016309_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/cdd.2014.81","volume":"21","author":"J Lemke","year":"2014","unstructured":"Lemke J, von Karstedt S, Zinngrebe J, Walczak H . Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014; 21: 1350\u20131364.","journal-title":"Cell Death Differ"},{"key":"BFonc2016309_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1182\/blood.V98.3.795","volume":"98","author":"CS Mitsiades","year":"2001","unstructured":"Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R et al. TRAIL\/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98: 795\u2013804.","journal-title":"Blood"},{"key":"BFonc2016309_CR4","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood.V99.6.2162","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP . Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002; 99: 2162\u20132171.","journal-title":"Blood"},{"key":"BFonc2016309_CR5","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/sj.leu.2402251","volume":"15","author":"LF Lincz","year":"2001","unstructured":"Lincz LF, Yeh TX, Spencer A . TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 2001; 15: 1650\u20131657.","journal-title":"Leukemia"},{"key":"BFonc2016309_CR6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/onc.2012.164","volume":"32","author":"LY Dimberg","year":"2013","unstructured":"Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL . On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2013; 32: 1341\u20131350.","journal-title":"Oncogene"},{"key":"BFonc2016309_CR7","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1182\/blood.V99.11.4079","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002; 99: 4079\u20134086.","journal-title":"Blood"},{"key":"BFonc2016309_CR8","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.4049\/jimmunol.180.3.1545","volume":"180","author":"LE Perez","year":"2008","unstructured":"Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C et al. Bone marrow stroma confers resistance to Apo2 ligand\/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol 2008; 180: 1545\u20131555.","journal-title":"J Immunol"},{"key":"BFonc2016309_CR9","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1038\/cddis.2011.78","volume":"2","author":"H Rauert","year":"2011","unstructured":"Rauert H, Stuhmer T, Bargou R, Wajant H, Siegmund D . TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. Cell Death Dis 2011; 2: e194.","journal-title":"Cell Death Dis"},{"key":"BFonc2016309_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano Y, Moschetta M, Manier S, Glavey S, Gorgun GT, Roccaro AM et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev 2015; 263: 160\u2013172.","journal-title":"Immunol Rev"},{"key":"BFonc2016309_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1385\/MO:19:3:133","volume":"19","author":"V Jurisic","year":"2002","unstructured":"Jurisic V, Colovic M . Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med Oncol 2002; 19: 133\u2013139.","journal-title":"Med Oncol"},{"key":"BFonc2016309_CR12","first-page":"65","volume":"10","author":"M Jourdan","year":"1999","unstructured":"Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B . Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999; 10: 65\u201370.","journal-title":"Eur Cytokine Netw"},{"key":"BFonc2016309_CR13","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3109\/10428194.2014.956313","volume":"56","author":"XS Wang","year":"2015","unstructured":"Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN et al. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma 2015; 56: 1335\u20131341.","journal-title":"Leuk Lymphoma"},{"key":"BFonc2016309_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/2162-3619-1-27","volume":"1","author":"T Latif","year":"2012","unstructured":"Latif T, Chauhan N, Khan R, Moran A, Usmani SZ . Thalidomide and its analogues in the treatment of multiple myeloma. Exp Hematol Oncol 2012; 1: 27.","journal-title":"Exp Hematol Oncol"},{"key":"BFonc2016309_CR15","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/ajh.23822","volume":"89","author":"C Geng","year":"2014","unstructured":"Geng C, Hou J, Zhao Y, Ke X, Wang Z, Qiu L et al. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. Am J Hematol 2014; 89: 1037\u20131042.","journal-title":"Am J Hematol"},{"key":"BFonc2016309_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.0105-2896.2006.00375.x","volume":"210","author":"A Hoffmann","year":"2006","unstructured":"Hoffmann A, Baltimore D . Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006; 210: 171\u2013186.","journal-title":"Immunol Rev"},{"key":"BFonc2016309_CR17","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1182\/blood-2003-09-3037","volume":"103","author":"Y Dai","year":"2004","unstructured":"Dai Y, Pei XY, Rahmani M, Conrad DH, Dent P, Grant S . Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 2004; 103: 2761\u20132770.","journal-title":"Blood"},{"key":"BFonc2016309_CR18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","volume":"12","author":"JJ Keats","year":"2007","unstructured":"Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131\u2013144.","journal-title":"Cancer Cell"},{"key":"BFonc2016309_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1600-065X.2011.01088.x","volume":"246","author":"SC Sun","year":"2012","unstructured":"Sun SC . The noncanonical NF-kappaB pathway. Immunol Rev 2012; 246: 125\u2013140.","journal-title":"Immunol Rev"},{"key":"BFonc2016309_CR20","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1002\/cncr.25190","volume":"116","author":"CM Annunziata","year":"2010","unstructured":"Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer 2010; 116: 3276\u20133284.","journal-title":"Cancer"},{"key":"BFonc2016309_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cytogfr.2010.06.002","volume":"21","author":"YM Thu","year":"2010","unstructured":"Thu YM, Richmond A . NF-kappaB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev 2010; 21: 213\u2013226.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFonc2016309_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","volume":"12","author":"CM Annunziata","year":"2007","unstructured":"Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115\u2013130.","journal-title":"Cancer Cell"},{"key":"BFonc2016309_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467\u2013472.","journal-title":"Nature"},{"key":"BFonc2016309_CR24","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/blood.V84.11.3850.bloodjournal84113850","volume":"84","author":"A Migliazza","year":"1994","unstructured":"Migliazza A, Lombardi L, Rocchi M, Trecca D, Chang CC, Antonacci R et al. Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2\/lyt-10 gene in lymphoid malignancies. Blood 1994; 84: 3850\u20133860.","journal-title":"Blood"},{"key":"BFonc2016309_CR25","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","volume":"115","author":"YN Demchenko","year":"2010","unstructured":"Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM . Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010; 115: 3541\u20133552.","journal-title":"Blood"},{"key":"BFonc2016309_CR26","doi-asserted-by":"publisher","first-page":"8428","DOI":"10.1038\/ncomms9428","volume":"6","author":"SD Vallabhapurapu","year":"2015","unstructured":"Vallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V et al. Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nat Commun 2015; 6: 8428.","journal-title":"Nat Commun"},{"key":"BFonc2016309_CR27","doi-asserted-by":"publisher","first-page":"e59127","DOI":"10.1371\/journal.pone.0059127","volume":"8","author":"F Cormier","year":"2013","unstructured":"Cormier F, Monjanel H, Fabre C, Billot K, Sapharikas E, Chereau F et al. Frequent engagement of RelB activation is critical for cell survival in multiple myeloma. PLoS One 2013; 8: e59127.","journal-title":"PLoS One"},{"key":"BFonc2016309_CR28","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.18632\/oncotarget.2128","volume":"5","author":"YN Demchenko","year":"2014","unstructured":"Demchenko YN, Brents LA, Li Z, Bergsagel LP, McGee LR, Kuehl MW . Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB. Oncotarget 2014; 5: 4554\u20134566.","journal-title":"Oncotarget"},{"key":"BFonc2016309_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/ncb2463","volume":"14","author":"L Busino","year":"2012","unstructured":"Busino L, Millman SE, Scotto L, Kyratsous CA, Basrur V, O'Connor O et al. Fbxw7alpha- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 2012; 14: 375\u2013385.","journal-title":"Nat Cell Biol"},{"key":"BFonc2016309_CR30","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.celrep.2014.11.024","volume":"9","author":"JV Almaden","year":"2014","unstructured":"Almaden JV, Tsui R, Liu YC, Birnbaum H, Shokhirev MN, Ngo KA et al. A pathway switch directs BAFF signaling to distinct NFkappaB transcription factors in maturing and proliferating B cells. Cell Rep 2014; 9: 2098\u20132111.","journal-title":"Cell Rep"},{"key":"BFonc2016309_CR31","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/ni.2446","volume":"13","author":"VF Shih","year":"2012","unstructured":"Shih VF, Davis-Turak J, Macal M, Huang JQ, Ponomarenko J, Kearns JD et al. Control of RelB during dendritic cell activation integrates canonical and noncanonical NF-kappaB pathways. Nat Immunol 2012; 13: 1162\u20131170.","journal-title":"Nat Immunol"},{"key":"BFonc2016309_CR32","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1128\/MCB.01469-07","volume":"28","author":"S Basak","year":"2008","unstructured":"Basak S, Shih VF, Hoffmann A . Generation and activation of multiple dimeric transcription factors within the NF-kappaB signaling system. Mol Cell Biol 2008; 28: 3139\u20133150.","journal-title":"Mol Cell Biol"},{"key":"BFonc2016309_CR33","doi-asserted-by":"publisher","first-page":"23278","DOI":"10.1074\/jbc.M300106200","volume":"278","author":"E Derudder","year":"2003","unstructured":"Derudder E, Dejardin E, Pritchard LL, Green DR, Korner M, Baud V . RelB\/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100. J Biol Chem 2003; 278: 23278\u201323284.","journal-title":"J Biol Chem"},{"key":"BFonc2016309_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud V, Karin M . Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Disc 2009; 8: 33\u201340.","journal-title":"Nat Rev Drug Disc"},{"key":"BFonc2016309_CR35","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1126\/science.274.5288.782","volume":"274","author":"AA Beg","year":"1996","unstructured":"Beg AA, Baltimore D . An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996; 274: 782\u2013784.","journal-title":"Science"},{"key":"BFonc2016309_CR36","doi-asserted-by":"publisher","first-page":"14794","DOI":"10.1073\/pnas.1410124111","volume":"111","author":"H Authier","year":"2014","unstructured":"Authier H, Billot K, Derudder E, Bordereaux D, Riviere P, Rodrigues-Ferreira S et al. IKK phosphorylates RelB to modulate its promoter specificity and promote fibroblast migration downstream of TNF receptors. Proc Natl Acad Sci USA 2014; 111: 14794\u201314799.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2016309_CR37","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/0092-8674(88)90143-2","volume":"55","author":"P Angel","year":"1988","unstructured":"Angel P, Hattori K, Smeal T, Karin M . The jun proto-oncogene is positively autoregulated by its product, Jun\/AP-1. Cell 1988; 55: 875\u2013885.","journal-title":"Cell"},{"key":"BFonc2016309_CR38","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226\u2013231.","journal-title":"Nature"},{"key":"BFonc2016309_CR39","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/onc.2010.481","volume":"30","author":"M Koslowski","year":"2011","unstructured":"Koslowski M, Luxemburger U, Tureci O, Sahin U . Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1alpha. Oncogene 2011; 30: 876\u2013882.","journal-title":"Oncogene"},{"key":"BFonc2016309_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccr.2012.06.007","volume":"22","author":"T Sanda","year":"2012","unstructured":"Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell 2012; 22: 209\u2013221.","journal-title":"Cancer Cell"},{"key":"BFonc2016309_CR41","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1038\/sj.emboj.7600391","volume":"23","author":"G Bonizzi","year":"2004","unstructured":"Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, Vu D et al. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J 2004; 23: 4202\u20134210.","journal-title":"EMBO J"},{"key":"BFonc2016309_CR42","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1097-2765(03)00227-2","volume":"11","author":"S Saccani","year":"2003","unstructured":"Saccani S, Pantano S, Natoli G . Modulation of NF-kappaB activity by exchange of dimers. Mol Cell 2003; 11: 1563\u20131574.","journal-title":"Mol Cell"},{"key":"BFonc2016309_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/0092-8674(95)90416-6","volume":"80","author":"F Weih","year":"1995","unstructured":"Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck RP et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B\/Rel family. Cell 1995; 80: 331\u2013340.","journal-title":"Cell"},{"key":"BFonc2016309_CR44","doi-asserted-by":"publisher","first-page":"27857","DOI":"10.1074\/jbc.M109.000950","volume":"284","author":"X Chen","year":"2009","unstructured":"Chen X, El Gazzar M, Yoza BK, McCall CE . The NF-kappaB factor RelB and histone H3 lysine methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin tolerance. J Biol Chem 2009; 284: 27857\u201327865.","journal-title":"J Biol Chem"},{"key":"BFonc2016309_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/ni.2151","volume":"13","author":"T Siggers","year":"2012","unstructured":"Siggers T, Chang AB, Teixeira A, Wong D, Williams KJ, Ahmed B et al. Principles of dimer-specific gene regulation revealed by a comprehensive characterization of NF-kappaB family DNA binding. Nat Immunol 2012; 13: 95\u2013102.","journal-title":"Nat Immunol"},{"key":"BFonc2016309_CR46","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.celrep.2014.07.037","volume":"8","author":"B Zhao","year":"2014","unstructured":"Zhao B, Barrera LA, Ersing I, Willox B, Schmidt SC, Greenfeld H et al. The NF-kappaB genomic landscape in lymphoblastoid B cells. Cell Rep 2014; 8: 1595\u20131606.","journal-title":"Cell Rep"},{"key":"BFonc2016309_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cytogfr.2008.04.005","volume":"19","author":"S Basak","year":"2008","unstructured":"Basak S, Hoffmann A . Crosstalk via the NF-kappaB signaling system. Cytokine Growth Factor Rev 2008; 19: 187\u2013197.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFonc2016309_CR48","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1038\/bcj.2015.3","volume":"5","author":"PJ Hengeveld","year":"2015","unstructured":"Hengeveld PJ, Kersten MJ . B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer J 2015; 5: e282.","journal-title":"Blood Cancer J"},{"key":"BFonc2016309_CR49","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2006.12.033","volume":"128","author":"S Basak","year":"2007","unstructured":"Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL et al. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 2007; 128: 369\u2013381.","journal-title":"Cell"},{"key":"BFonc2016309_CR50","doi-asserted-by":"crossref","unstructured":"Banoth B, Chatterjee B, Vijayaragavan B, Prasad MV, Roy P, Basak S . Stimulus-selective crosstalk the NF-kappaB signaling system reinforces innate immune response to alleviate gut infection. Elife 2015; 4: e05648.","DOI":"10.7554\/eLife.05648"},{"key":"BFonc2016309_CR51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0076-6879(06)11009-5","volume":"411","author":"AI Saeed","year":"2006","unstructured":"Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA et al. TM4 microarray software suite. Methods Enzymol 2006; 411: 134\u2013193.","journal-title":"Methods Enzymol"},{"key":"BFonc2016309_CR52","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.cdd.4400441","volume":"5","author":"WX Zong","year":"1998","unstructured":"Zong WX, Bash J, Gelinas C . Rel blocks both anti-Fas- and TNF alpha-induced apoptosis and an intact Rel transactivation domain is essential for this effect. Cell Death Differ 1998; 5: 963\u2013972.","journal-title":"Cell Death Differ"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2016309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2016309","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2016309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:59:55Z","timestamp":1684472395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2016309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,19]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFonc2016309"],"URL":"https:\/\/doi.org\/10.1038\/onc.2016.309","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,19]]},"assertion":[{"value":"15 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}